Kaleido Biosciences EBIT

Kaleido Biosciences (KLDO) currently reports a EBIT of $0 as of September 2023. That compares with $-66M in the prior-year period — up 100.0% year over year. That is below the Healthcare sector average of $22B. Use the charts on this page to explore Kaleido Biosciences's EBIT history and peer comparisons.

Kaleido Biosciences's EBIT increased from $-66M to $0 — a 100.0% year-over-year increase (period ending September 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Kaleido Biosciences's EBIT of $0 is lower than the Healthcare sector average of $22B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Kaleido Biosciences reported $0 in EBIT as of September 2023. That compares with $-66M in the prior-year period — up 100.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $22B. From there, open related valuation or income-statement pages for Kaleido Biosciences, and consider following KLDO for alerts when major investors trade the stock.